MCID: THY022
MIFTS: 57

Thymic Carcinoma

Categories: Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Thymic Carcinoma

MalaCards integrated aliases for Thymic Carcinoma:

Name: Thymic Carcinoma 12 74 58 54 15 17
Malignant Thymoma 12 58
Thymoma, Malignant 12

Characteristics:

Orphanet epidemiological data:

58
thymic carcinoma
Inheritance: Not applicable; Age of onset: Adult; Age of death: any age;

Classifications:



External Ids:

Disease Ontology 12 DOID:3284
MeSH 44 D013945
NCIt 50 C7569
SNOMED-CT 67 128717008
ICD10 via Orphanet 33 C37
UMLS via Orphanet 72 C0205969 C1322286
Orphanet 58 ORPHA99868
UMLS 71 C0205969

Summaries for Thymic Carcinoma

Disease Ontology : 12 A thymus cancer that derives from epithelial cells. The tumor cells in a thymic carcinoma look very different from the normal cells of the thymus, grow more quickly, and have usually spread to other parts of the body when the cancer is found.

MalaCards based summary : Thymic Carcinoma, also known as malignant thymoma, is related to lymphoepithelioma-like thymic carcinoma and type c thymoma. An important gene associated with Thymic Carcinoma is KIT (KIT Proto-Oncogene, Receptor Tyrosine Kinase), and among its related pathways/superpathways are NF-kappaB Signaling and Cytoskeletal Signaling. The drugs Paclitaxel and Albumin-Bound Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include thymus, lymph node and bone marrow, and related phenotypes are mediastinal lymphadenopathy and neoplasm of the thymus

Wikipedia : 74 Thymic carcinoma is a rare type of thymus gland cancer. It usually spreads, has a high risk of... more...

Related Diseases for Thymic Carcinoma

Diseases related to Thymic Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 855)
# Related Disease Score Top Affiliating Genes
1 lymphoepithelioma-like thymic carcinoma 32.5 KIT CD5
2 type c thymoma 32.3 KIT CD5
3 thymus adenocarcinoma 32.1 KRT20 CEACAM5 CD5
4 epithelial malignant thymoma 31.7 TG CD5
5 thymic epithelial tumor 31.1 KIT CD5
6 thymus cancer 30.7 TP53 SYP PTPRC NKX2-1 KRT7 KIT
7 exanthem 30.5 PDCD1 KIT EGFR CD274
8 secretory meningioma 30.4 MUC1 KRT7 CEACAM5
9 pneumothorax 30.3 NKX2-1 MUC1 CALB2
10 spindle cell thymoma 30.3 MUC1 ENO2 CD5 CALB2
11 thymus sarcomatoid carcinoma 30.2 SYP CD5
12 spindle cell sarcoma 30.2 MUC1 KRT7 KIT
13 thymus lipoma 29.9 KRT20 KRT19
14 thymus basaloid carcinoma 29.9 SYP PAX8 NKX2-1 CD5
15 appendix adenocarcinoma 29.9 SYP KRT7 KRT20 CEACAM5
16 thymoma 29.9 TP63 TP53 SYP PTPRC NKX2-1 KRT7
17 cystitis 29.8 TP53 KRT7 KRT20 KIT
18 malignant fibrous histiocytoma 29.8 TP53 PTPRC MUC1 KIT
19 choroid plexus cancer 29.8 TP53 SYP CEACAM5
20 carcinoid tumors, intestinal 29.8 SYP NKX2-1 ENO2
21 myoma 29.7 TP53 KIT EGFR CEACAM5
22 mesothelioma, malignant 29.7 NKX2-1 MUC1 KRT7 KRT20 CEACAM5 CALB2
23 meningioma, familial 29.6 TP53 SYP MUC1 EGFR CALB2
24 gastrointestinal stromal tumor 29.6 TP53 SYP KIT ENO2 EGFR
25 ectopic thymus 29.6 TG NKX2-1 CD5
26 neuroendocrine tumor 29.5 SYP NKX2-1 KRT20 KRT19 ENO2 CD274
27 sarcoma, synovial 29.5 MUC1 KRT7 KRT19 KIT CALB2
28 lung squamous cell carcinoma 29.5 TP63 TP53 KRT19 EGFR CD274
29 thyroid carcinoma, familial medullary 29.4 TG NKX2-1 CEACAM5
30 pleural disease 29.4 TP53 EGFR CEACAM5 CD274 CALB2
31 adenocarcinoma 29.4 TP53 NKX2-1 MUC1 KRT7 KIT EGFR
32 lymphoepithelioma-like carcinoma 29.4 PDCD1 MUC1 KRT7 KRT20 KRT19 KRT18
33 leukemia, acute myeloid 29.3 TP53 PTPRC KIT EGFR CD5 CD274
34 mediastinal cancer 29.3 SYP PTPRC NKX2-1 KRT7 KIT ENO2
35 benign mesothelioma 29.3 NKX2-1 KRT7 KRT20 KRT19 CEACAM5 CALB2
36 malignant pleural mesothelioma 29.3 TP53 NKX2-1 MUC1 EGFR CD274 CALB2
37 keratinizing squamous cell carcinoma 29.2 TP53 SYP NKX2-1 KRT7 EGFR CEACAM5
38 squamous cell carcinoma 29.2 TP63 TP53 MUC1 KRT7 KRT19 EGFR
39 lymphoma 29.2 TP53 PTPRC PDCD1 KIT EGFR CD5
40 peripheral nervous system disease 29.1 TP53 SYP PTPRC KIT ENO2 EGFR
41 papillary thymic adenocarcinoma 29.1 TG SYP CEACAM5 CD5 CALB2
42 papillary adenocarcinoma 29.0 TP53 NKX2-1 MUC1 KRT7 KRT19 CEACAM5
43 adenoid cystic carcinoma 29.0 TP63 TP53 MUC1 KRT7 KRT20 KRT19
44 thyroid gland medullary carcinoma 29.0 TG SYP PAX8 NKX2-1 CEACAM5
45 goiter 28.9 TG PAX8 NKX2-1 KRT19
46 adenoma 28.9 TP53 TG SYP MUC1 KRT7 KRT20
47 basaloid squamous cell carcinoma 28.8 TP63 TP53 SYP KRT7 KRT20 KRT19
48 lung cancer susceptibility 3 28.7 TP53 NKX2-1 MUC1 KRT7 KRT20 KRT19
49 large cell neuroendocrine carcinoma 28.6 SYP NKX2-1 KRT7 KRT20 KRT18 KIT
50 neuroendocrine carcinoma 28.5 TP63 SYP PTPRC NKX2-1 MUC1 KRT7

Graphical network of the top 20 diseases related to Thymic Carcinoma:



Diseases related to Thymic Carcinoma

Symptoms & Phenotypes for Thymic Carcinoma

Human phenotypes related to Thymic Carcinoma:

58 31 (show all 13)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 mediastinal lymphadenopathy 58 31 hallmark (90%) Very frequent (99-80%) HP:0100721
2 neoplasm of the thymus 58 31 hallmark (90%) Very frequent (99-80%) HP:0100521
3 palpebral edema 58 31 frequent (33%) Frequent (79-30%) HP:0100540
4 dyspnea 58 31 frequent (33%) Frequent (79-30%) HP:0002094
5 cough 58 31 frequent (33%) Frequent (79-30%) HP:0012735
6 chest pain 58 31 frequent (33%) Frequent (79-30%) HP:0100749
7 diaphragmatic paralysis 58 31 frequent (33%) Frequent (79-30%) HP:0006597
8 abnormal vena cava morphology 58 31 frequent (33%) Frequent (79-30%) HP:0005345
9 hyperhidrosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000975
10 fatigue 58 31 occasional (7.5%) Occasional (29-5%) HP:0012378
11 weight loss 58 31 occasional (7.5%) Occasional (29-5%) HP:0001824
12 fatigable weakness 58 31 occasional (7.5%) Occasional (29-5%) HP:0003473
13 edema 58 Frequent (79-30%)

MGI Mouse Phenotypes related to Thymic Carcinoma:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.27 CD274 EGFR ENO2 KIT KRT19 KRT7
2 growth/size/body region MP:0005378 10.25 CD5 EGFR ENO2 KIT KRT18 KRT19
3 nervous system MP:0003631 10.18 CALB2 CD5 EGFR ENO2 KIT KRT19
4 endocrine/exocrine gland MP:0005379 10.16 EGFR KIT KRT19 NKX2-1 PAX8 PDCD1
5 digestive/alimentary MP:0005381 10.08 EGFR KIT KRT19 NKX2-1 PTPRC TG
6 no phenotypic analysis MP:0003012 10.02 CD274 CD5 EGFR KIT KRT19 NKX2-1
7 neoplasm MP:0002006 10.01 EGFR KIT KRT19 NKX2-1 PDCD1 PTPRC
8 normal MP:0002873 10 CALB2 CD5 EGFR KIT KRT19 NKX2-1
9 renal/urinary system MP:0005367 9.76 EGFR KIT KRT7 PAX8 PDCD1 PTPRC
10 respiratory system MP:0005388 9.61 EGFR ENO2 KIT KRT19 NKX2-1 PDCD1
11 skeleton MP:0005390 9.36 CD274 EGFR KIT KRT19 NKX2-1 PAX8

Drugs & Therapeutics for Thymic Carcinoma

Drugs for Thymic Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 68)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 4 33069-62-4 36314
2 Albumin-Bound Paclitaxel Phase 4
3 Tubulin Modulators Phase 4
4 Antimitotic Agents Phase 4
5
Etoposide Approved Phase 3 33419-42-0 36462
6 Etoposide phosphate Phase 3
7
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
8
Octreotide Approved, Investigational Phase 2 83150-76-9 383414 6400441
9
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
10
Belinostat Approved, Investigational Phase 2 866323-14-0
11
Bevacizumab Approved, Investigational Phase 2 216974-75-3
12
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 446556 60843
13
Levoleucovorin Approved, Investigational Phase 2 68538-85-2 149436
14
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
15
nivolumab Approved Phase 1, Phase 2 946414-94-4
16
ramucirumab Approved, Investigational Phase 2 947687-13-0
17
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
18
Nedaplatin Approved, Investigational Phase 2 95734-82-0
19
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
20
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
21
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
22
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
23
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
24
Pembrolizumab Approved Phase 2 1374853-91-4
25
Lenvatinib Approved, Investigational Phase 2 417716-92-8
26
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
27
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
28
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
29
Lexatumumab Investigational Phase 2 845816-02-6
30
Saracatinib Investigational Phase 2 379231-04-6
31
Maleic acid Experimental Phase 2 110-16-7 444266
32 Imatinib Mesylate Phase 2 220127-57-1 123596
33 Anti-Inflammatory Agents Phase 2
34 Hormone Antagonists Phase 2
35 Hormones Phase 2
36 glucocorticoids Phase 2
37 Antineoplastic Agents, Hormonal Phase 2
38 Gastrointestinal Agents Phase 2
39 Histone Deacetylase Inhibitors Phase 2
40
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
41 Folic Acid Antagonists Phase 2
42 Vitamin B Complex Phase 2
43 Folate Phase 2
44 Vitamin B9 Phase 2
45 Insulin, Globin Zinc Phase 2
46 Mitogens Phase 2
47 insulin Phase 2
48 Immunoglobulins Phase 2
49 Antibodies Phase 2
50 Antibodies, Monoclonal Phase 2

Interventional clinical trials:

(show all 40)
# Name Status NCT ID Phase Drugs
1 Single-Arm Study to Carbo-paclitaxel/ Nab-paclitaxel Combined With Pembrolizumab as the First Line Therapy in Treating Patients With Locally Advanced or Metastatic Invasive Thymoma and Thymic Carcinoma That Cannot Be Removed by Surgery Recruiting NCT04554524 Phase 4 Chemotherapy+Pembrolizumab.
2 A Randomized Phase III Study of Adjuvant Radiotherapy Versus Adjuvant Radiochemotherapy in Patients With Incomplete ResectionThymoma or Thymic Carcinoma Recruiting NCT02633514 Phase 3 Cisplatin;Etoposide
3 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
4 Phase II Study Of Carboplatin Plus Paclitaxel Treatment Of Advanced Thymoma Or Thymic Carcinoma Completed NCT00010257 Phase 2 carboplatin;paclitaxel
5 Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy Completed NCT02049047 Phase 2 Everolimus
6 Phase II Study of Octreotide Treatment of Advanced, Recurrent Thymoma Completed NCT00003283 Phase 2 octreotide acetate;prednisone
7 A Phase II, Non-comparative, Open Label, Multi-center Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma Completed NCT02623127 Phase 2 Sunitinib
8 Phase II Study of Trimodality Therapy for Patients With Thymoma or Thymic Carcinoma at Significant Risk for Recurrence Completed NCT00387868 Phase 2 cisplatin and etoposide
9 A Multicenter Phase II Study of Belinostat (PXD-101) in Previously Chemotherapy Treated Thymoma and Thymic Carcinoma Completed NCT00589290 Phase 2 Belinostat (PDX101)
10 A Phase II Study of Erlotinib Plus Bevacizumab in the Treatment of Advanced Thymoma and Thymic Carcinoma Completed NCT00369889 Phase 2 bevacizumab;Erlotinib
11 Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma Completed NCT00198133 Phase 2 Premetrexed (Alimta)
12 Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy Completed NCT00965250 Phase 2 IMC-12
13 A Multicenter, Phase II Trial of Pembrolizumab and Sunitinib in Refractory Advanced Thymic Carcinoma Recruiting NCT03463460 Phase 2 Sunitinib Malate
14 Phase 1/2 Study to Evaluate the Safety and Preliminary Activity of Nivolumab in Combination With Vorolanib in Patients With Refractory Thoracic Tumors Recruiting NCT03583086 Phase 1, Phase 2 VEGFR/PDGFR Dual Kinase Inhibitor X-82
15 Improving Treatment Strategies in Thymic Epithelial Tumors: a TYME Collaborative Effort Recruiting NCT03921671 Phase 2
16 A Randomized Phase II Trial of Carboplatin-Paclitaxel With or Without Ramucirumab in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma Recruiting NCT03694002 Phase 2 Carboplatin;Paclitaxel
17 A Prospective, Phase Ⅱ Study of Thymosin a1 During Chemoradiotherapy For Unresectable Thymoma and Thymic Carcinoma Recruiting NCT03663764 Phase 2 Thymosin a1
18 A Phase 2, Open-Label, Multi-Center Study to Evaluate Efficacy, Safety and Tolerability of KN046 in Subjects With Thymic Carcinoma Recruiting NCT04469725 Phase 2 KN046
19 An Open-Label, Single Arm, Multicenter Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma Recruiting NCT04321330 Phase 2 Atezolizumab
20 Phase II Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial) Recruiting NCT03449173 Phase 2 Sunitinib
21 A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy Recruiting NCT03076554 Phase 2 Avelumab
22 Single-arm, Multicentre, Phase II Study of Immunotherapy in Patients With Type B3 Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy Recruiting NCT03134118 Phase 2 Nivolumab
23 A Phase II, Open-Label Trial of Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma Recruiting NCT04417660 Phase 2 M7824
24 Pembrolizumab (MK-3475) and Epacadostat (INCB024360) in Thymic Carcinomas Active, not recruiting NCT02364076 Phase 2 Pembrolizumab;Epacadostat
25 A Phase II Trial of Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma (BMS #CA225-331/Lilly Trial Alias I4E-US-X007) Active, not recruiting NCT01025089 Phase 2 Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide
26 A Phase II Study of Sunitinib in Patients With Advanced Relapsed or Refractory Thymoma or Thymic Carcinoma With at Least One Prior Line of Platinum-Based Systemic Chemotherapy Active, not recruiting NCT01621568 Phase 2 Sunitinib
27 A Multicentric, Open-Label, Single Arm Phase II Study To Evaluate The Efficacy And Safety Of The Combination Of PEmbrolizumab And Lenvatinib In Pre-Treated Thymic Carcinoma PaTIents. PECATI. Not yet recruiting NCT04710628 Phase 2 Pembrolizumab;Lenvatinib 10 mg
28 A Phase II Study of Paclitaxel and Cisplatin in Previously Untreated, Unresectable Invasive Thymoma or Thymic Carcinoma Terminated NCT00818090 Phase 2 paclitaxel and cisplatin
29 Phase II Trial of AZD0530 for Patients With Relapsed/Refractory Thymic Malignancies (Thymoma and Thymic Carcinoma) Terminated NCT00718809 Phase 2 saracatinib
30 Phase II Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy Terminated NCT01301391 Phase 2 Milciclib Maleate
31 Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma Previously Treated With Chemotherapy Terminated NCT01011439 Phase 2 Milciclib Maleate
32 Feasibility Trial of Pembrolizumab in Unresectable Thymoma and Thymic Carcinoma Unknown status NCT03295227 Phase 1 Pembrolizumab
33 Pilot Study of Imatinib (Gleevec) as Treatment for Advanced Thymic Carcinoma Completed NCT00314873 Phase 1 Gleevec (imatinib)
34 An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects With Solid Tumors or Lymphoma Recruiting NCT03556228 Phase 1 VMD-928 300 mg Tablets or 100 mg Capsules
35 Phase 1b Multi-indication Study of Anetumab Ravtansine (BAY94-9343) in Patients With Mesothelin Expressing Advanced or Recurrent Malignancies Active, not recruiting NCT03102320 Phase 1 Cisplatin;Gemcitabine;Anetumab ravtansine (BAY94-9343)
36 Phase Ⅱ Study of Concurrent Chemoradiotherapy for Limited Advanced Unresectable Thymic Epithelial Tumors Completed NCT02636556
37 Prospective Ⅱ Study of Stereotactic Body Radiation Therapy for Thymoma and Thymic Carcinoma: Therapeutic Effect and Toxicity Assessment Completed NCT03078699
38 Biological Analysis of a Series of Thymoma and Thymic Carcinoma: Genetic Aberrations and Potential Therapy Targets. Completed NCT00965627
39 Can MRI Replace CT in the Evaluation of Thymoma? Active, not recruiting NCT03968315
40 Randomized, Multicenter, Phase III Trial to Assess Conformal Post-operative Radiotherapy vs. Surveillance After Complete Resection of Stage II/III Thymoma Not yet recruiting NCT04731610

Search NIH Clinical Center for Thymic Carcinoma

Genetic Tests for Thymic Carcinoma

Anatomical Context for Thymic Carcinoma

MalaCards organs/tissues related to Thymic Carcinoma:

40
Thymus, Lymph Node, Bone Marrow, T Cells, Pituitary, Neutrophil, Bone

Publications for Thymic Carcinoma

Articles related to Thymic Carcinoma:

(show top 50) (show all 1734)
# Title Authors PMID Year
1
Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. 61 54
19861435 2009
2
Absence of gene mutations in KIT-positive thymic epithelial tumors. 61 54
18486988 2008
3
Mutational status of EGFR and KIT in thymoma and thymic carcinoma. 61 54
18448188 2008
4
Expression of p63 in thymomas and normal thymus. 61 54
17276940 2007
5
Carcinoma showing thymus-like differentiation of the thyroid (CASTLE): a comparative study: evidence of thymic differentiation and solid cell nest origin. 54 61
16861971 2006
6
Immunohistochemical KIT (CD117) expression in thymic epithelial tumors. 61 54
16002927 2005
7
Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. 54 61
15201427 2004
8
Tyrosine kinase receptor expression in thymomas. 54 61
14762710 2004
9
Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma. 54 61
14652817 2003
10
Neuroendocrine differentiation is a common feature of thymic carcinoma. 54 61
9737237 1998
11
A case of sarcomatoid carcinoma of the thymus. 54 61
9103218 1997
12
Differential diagnosis of thymic carcinoma and lung carcinoma with the use of antibodies to cytokeratins. 54 61
8523878 1995
13
Carcinoma of the thymus with clear-cell features. Report of eight cases and review of the literature. 54 61
7793482 1995
14
CD5 expression in thymic carcinoma. 54 61
7519823 1994
15
Cytokeratins in normal thymus and thymic epithelial tumors. 54 61
7677978 1993
16
An Intraocular Thymic Metastasis Identified on 18F-FDG PET/CT Before and After Treatment. 61
33234936 2021
17
Thymic Epithelial Neoplasms: Tumor-Node-Metastasis Staging. 61
33551080 2021
18
Thymic Epithelial Neoplasms: Radiologic-Pathologic Correlation. 61
33551079 2021
19
Are volume-dependent parameters in positron emission tomography predictive of postoperative recurrence after resection in patients with thymic carcinoma? 61
32535710 2021
20
Thymic epithelial tumors: Do we know all the prognostic factors? 61
33386778 2021
21
[Intrathyroid thymic carcinoma: a case report]. 61
33557490 2021
22
SS-A52 antigen expression in thymic carcinoma accompanied with Sjögren syndrome: A case report. 61
33592902 2021
23
Malignant thymoma and chronic inflammatory demyelinating neuropathy. 61
33269493 2021
24
Epidemiology of thymic epithelial tumors: 22-years experience from a single-institution. 61
33356008 2021
25
18F-FDG-PET/CT predicts grade of malignancy and invasive potential of thymic epithelial tumors. 61
32734427 2021
26
Expression of cathepsins B, D and K in thymic epithelial tumours. 61
32467319 2021
27
Proton Beam Therapy for Thymic Carcinoma with Pericardial Involvement. 61
33604417 2021
28
Common and rare carcinomas of the thymus. 61
33389148 2021
29
Squamous Cell Carcinoma of Thymus Presenting as Constrictive Pericarditis Diagnosed With 18F-FDG PET/CT. 61
32701799 2021
30
Pigmented spindle cell variant of a thymic atypical carcinoid in an octogenarian. 61
33409736 2021
31
Prognostic factors of stage I thymic epithelial tumors. 61
32621280 2021
32
Pathological and clinical features of enteric adenocarcinoma of the thymus. A pooled analysis of cases from a reference center and systematic review of the literature. 61
33296826 2021
33
Immunotherapy vs platinum for advanced or metastatic thymic carcinoma: A protocol for systematic review and meta analysis. 61
33545943 2021
34
Mutation Profile of Thymic Carcinoma and Thymic Neuroendocrine Tumor by Targeted Next-generation Sequencing. 61
33414055 2020
35
Racial Disparity in Surgical Therapy for Thymic Malignancies. 61
33301745 2020
36
Correlation of genomic alterations and PD-L1 expression in thymoma. 61
33447447 2020
37
Comparison of PD-L1 immunohistochemical assays and the significance of PD-L1 expression in thymoma. 61
33447446 2020
38
Immunotherapy for thymoma. 61
33447455 2020
39
Epidemiology of thymoma. 61
33447443 2020
40
[Thymoma and squamous thymic carcinoma diagnosis; experience from the RYTHMIC network]. 61
33309329 2020
41
Durable efficacy of anlotinib in a patient with advanced thymic squamous cell carcinoma after multiline chemotherapy and apatinib: A case report and literature review. 61
32997432 2020
42
Role of modern neoadjuvant chemoradiotherapy in locally advanced thymic epithelial neoplasms. 61
33174515 2020
43
Severe dermatomyositis revealing a thymic carcinoma: Did rituximab delay the diagnosis? 61
32667098 2020
44
Durable Response in Patients With Thymic Carcinoma Treated With Pembrolizumab After Prolonged Follow-Up. 61
33248322 2020
45
Octreotide in the treatment of malignant thymoma - Case report. 61
32982594 2020
46
Everolimus in the treatment of metastatic thymic epithelial tumors. 61
33007678 2020
47
Superior Vena Cava Syndrome Due to Thymic Carcinoma. 61
33391908 2020
48
Therapeutic plasma exchange as adjunct therapy in 3 dogs with myasthenia gravis and myasthenia-like syndrome. 61
33217167 2020
49
Predictive Features of Thymic Carcinoma and High-Risk Thymomas Using Random Forest Analysis. 61
31996651 2020
50
Interobserver variation in the classification of thymic lesions including biopsies and resection specimens in an international digital microscopy panel. 61
32506527 2020

Variations for Thymic Carcinoma

Cosmic variations for Thymic Carcinoma:

9 (show all 36)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM105695698 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.376T>A p.Y126N 17:7675236-7675236 6
2 COSM142891951 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.376T>A p.Y126N 17:7675236-7675236 6
3 COSM87975416 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.376T>A p.Y126N 17:7675236-7675236 6
4 COSM142627127 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.259T>A p.Y87N 17:7675236-7675236 6
5 COSM121944830 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.-21T>A p.? 17:7675236-7675236 6
6 COSM106116533 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.376T>A p.Y126N 17:7675236-7675236 6
7 COSM144072853 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.343T>A p.Y115N 17:7675236-7675236 6
8 COSM144363948 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.259T>A p.Y87N 17:7675236-7675236 6
9 COSM122332176 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.-21T>A p.? 17:7675236-7675236 6
10 COSM93250189 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.376T>A p.Y126N 17:7675236-7675236 6
11 COSM145076506 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.259T>A p.Y87N 17:7675236-7675236 6
12 COSM122804157 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.-21T>A p.? 17:7675236-7675236 6
13 COSM144718880 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.259T>A p.Y87N 17:7675236-7675236 6
14 COSM144140974 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.-102T>A p.? 17:7675236-7675236 6
15 COSM112319052 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.376T>A p.Y126N 17:7675236-7675236 6
16 COSM143214478 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.-102T>A p.? 17:7675236-7675236 6
17 COSM143433019 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.259T>A p.Y87N 17:7675236-7675236 6
18 COSM111826108 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.376T>A p.Y126N 17:7675236-7675236 6
19 COSM144005441 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.-102T>A p.? 17:7675236-7675236 6
20 COSM103083119 SMAD4 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.1081C>T p.R361C 18:51065548-51065548 6
21 COSM139771670 SMAD4 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.793C>T p.R265C 18:51065548-51065548 6
22 COSM91380576 SMAD4 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.1081C>T p.R361C 18:51065548-51065548 6
23 COSM88596522 PREX2 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.107G>T p.R36L 8:67952501-67952501 6
24 COSM88408638 NOTCH2 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.3359G>A p.C1120Y 1:119937445-119937445 6
25 COSM87667907 KMT2D thymus,NS,thymic carcinoma,undifferentiated carcinoma c.12634C>T p.R4212W 12:49032071-49032071 6
26 COSM88314740 KIT thymus,NS,thymic carcinoma,undifferentiated carcinoma c.1657T>A p.Y553N 4:54727425-54727425 6
27 COSM132270273 KDM6A thymus,NS,thymic carcinoma,undifferentiated carcinoma c.2768C>T p.A923V 23:45078488-45078488 6
28 COSM101719617 KDM6A thymus,NS,thymic carcinoma,undifferentiated carcinoma c.2870C>T p.A957V 23:45078488-45078488 6
29 COSM145420036 KDM6A thymus,NS,thymic carcinoma,undifferentiated carcinoma c.*1915C>T p.? 23:45078488-45078488 6
30 COSM143359668 KDM6A thymus,NS,thymic carcinoma,undifferentiated carcinoma c.3005C>T p.A1002V 23:45078488-45078488 6
31 COSM102181889 KDM6A thymus,NS,thymic carcinoma,undifferentiated carcinoma c.2921C>T p.A974V 23:45078488-45078488 6
32 COSM132025397 KDM6A thymus,NS,thymic carcinoma,undifferentiated carcinoma c.2714C>T p.A905V 23:45078488-45078488 6
33 COSM85170206 IL7R thymus,NS,thymic carcinoma,undifferentiated carcinoma c.537+1G>T p.? 5:35871214-35871214 6
34 COSM121730466 IL7R thymus,NS,thymic carcinoma,undifferentiated carcinoma c.537+1G>T p.? 5:35871214-35871214 6
35 COSM143857324 FAT1 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.12712A>G p.K4238E 4:186596834-186596834 6
36 COSM110448949 FAT1 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.12706A>G p.K4236E 4:186596834-186596834 6

Expression for Thymic Carcinoma

Search GEO for disease gene expression data for Thymic Carcinoma.

Pathways for Thymic Carcinoma

Pathways related to Thymic Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 12.07 PTPRC PDCD1 KIT CEACAM5 CD274
2 11.84 MUC1 KRT7 KRT20 KRT19 KRT18
3 11.28 TP53 KIT EGFR
4 10.99 PTPRC KIT CEACAM5 CD5

GO Terms for Thymic Carcinoma

Cellular components related to Thymic Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell periphery GO:0071944 9.33 PTPRC KRT19 KRT18
2 intermediate filament GO:0005882 9.26 KRT7 KRT20 KRT19 KRT18
3 external side of plasma membrane GO:0009897 9.1 PTPRC PDCD1 KRT18 KIT CD5 CD274

Biological processes related to Thymic Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 keratinization GO:0031424 9.71 KRT7 KRT20 KRT19 KRT18
2 viral process GO:0016032 9.63 TP53 PTPRC KRT7 KRT19 KRT18 EGFR
3 hematopoietic progenitor cell differentiation GO:0002244 9.54 TP53 PTPRC KIT
4 tongue development GO:0043586 9.46 KIT EGFR
5 bone marrow development GO:0048539 9.43 TP53 PTPRC
6 T cell costimulation GO:0031295 9.43 PDCD1 CD5 CD274
7 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.32 TP53 MUC1
8 cornification GO:0070268 9.26 KRT7 KRT20 KRT19 KRT18
9 thyroid gland development GO:0030878 8.8 TG PAX8 NKX2-1

Molecular functions related to Thymic Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription regulatory region sequence-specific DNA binding GO:0000976 9.46 TP63 TP53 PAX8 NKX2-1
2 MDM2/MDM4 family protein binding GO:0097371 8.96 TP63 TP53
3 p53 binding GO:0002039 8.8 TP63 TP53 MUC1

Sources for Thymic Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....